A Phase I, Randomised, Single-dose, Open-label, 3-period, 3-treatment, 3-way Crossover Study to Assess the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Balcinrenone/Dapagliflozin (Primary) ; Quinidine
- Indications Heart failure; Renal failure
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 31 May 2025 Status changed from not yet recruiting to recruiting.
- 27 May 2025 New trial record